Cromene Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 33.75%
- Profit Growth 86.62%
- Ebitda 86.62%
- Net Worth -14.78%
- Total Assets -70.13%
About Cromene Life Sciences
Cromene Life Sciences Private Limited (CLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 April 2016 (Eight years and nine months 12 days old ). Its registered office is in Faridabad, Haryana, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Sharma, Kaushlya Devi, and Subhash Pasrija serve as directors at the Company.
Company Details
-
Location
Faridabad, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290HR2016PTC063844
-
Company No.
063844
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Apr 2016
-
Date of AGM
26 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Cromene Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Sharma
|
Director | 30-Dec-2019 | Current |
|
Kaushlya Devi
|
Director | 30-Aug-2019 | Current |
|
Subhash Pasrija
|
Director | 30-Aug-2019 | Current |
Financial Performance of Cromene Life Sciences.
Cromene Life Sciences Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 33.75% increase. The company also saw a substantial improvement in profitability, with a 86.62% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cromene Life Sciences?
In 2019, Cromene Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Presude Lifesciences Private LimitedKaushlya Devi is a mutual person
-
Celeste Life Sciences Private LimitedAnil Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cromene Life Sciences?
Unlock and access historical data on people associated with Cromene Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cromene Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cromene Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
